In-Hospital Initiation of Lipid-Lowering Agents Might Become Standard Practice.
ORLANDO, FLA. -- Routine initiation of lipid-lowering drug therapy during hospitalization for an acute coronary syndrome is on the verge of being declared the standard of care in clinical practice. The American Heart Association is circulating a draft version of recommendations urging physicians to consider initiating lipid-lowering...

Antiretrovirals may inhibit lipid-lowering therapy.
LOS ANGELES -- HIV-positive patients on antiretroviral therapy who are prescribed lipid-lowering agents do not respond to those drugs as well as other patients do, according to a large retrospective study. The HIV patients were 57% as likely to reach the National Cholesterol Education Program's Adult Treatment...

Prescribed drugs, supplements tied to liver injury: antimicrobials are the most frequent offenders, with some CNS and immunomodulatory agents following.
A wide variety of prescription and nonprescription medications and nutritional supplements are at the root of drug-induced liver injury in the United States. Moreover, combinations of potentially hepatotoxic agents, rather than single agents, account for at least 20% of cases reported to the Drug-Induced Liver Injury Network...

VAP(R) Cholesterol Test Helps Researchers Identify Treatment Effects of Combination Therapy.
Coadministration of ezetimibe/simvastatin and fenofibrate results in more favorable lipid profile in mixed hyperlipidemia patients BIRMINGHAM, Ala., Nov. 10 /PRNewswire/ -- Using the VAP Cholesterol Test from Atherotech, Inc., investigators led by Michel Farnier M.D., of Point Medical, Rond Point de la Nation, Dijon, France, have reported...

Lipid-lowering drug benefits similar for diabetics.
Lipid-lowering agents, particularly statins, significantly reduce cardiovascular risk in people with diabetes, to the extent that these patients may benefit from the drugs even more than nondiabetics do, according to Dr. Joao Costa of the University of Lisbon and associates. Dr. Costa and associates reviewed 12 large...

Antiretrovirals found to impair lipid lowering.
LOS ANGELES -- HIV-positive patients on antiretroviral therapy who are prescribed lipid-lowering agents do not respond to those drugs as well as other patients do, according to a large retrospective study by Kaiser Permanente. The HIV patients were only 57% as likely to reach the National Cholesterol...

Lipid lowering: known knowns and known unknowns.
We know that primary care teams are now following a structured and systematic approach to reducing CV risk in people with diabetes, including the extensive use of lipid-lowering treatment. A series of important trials have informed contemporary guidance, as well as the treatment-to-target option of a total cholesterol level...

Diabetics benefit from statins.
Lipid-lowering agents, particularly statins, significantly reduce cardiovascular risk in people with diabetes, to the extent that these patients may benefit from the drugs even more than nondiabetics do, said Dr. Joao Costa of the University of Lisbon and associates. They conducted a metaanalysis of 12 large studies...

Brain Res Rev: Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans.
2007;56:443-471. Neural membranes are composed of glycerophospholipids, sphingolipids, cholesterol and proteins. The distribution of these lipids within the neural membrane is not random but organized. Neural membranes contain lipid rafts or microdomains that are enriched in sphingolipids and cholesterol. These rafts act as platforms for the generation...

Cholesterol reduction using psyllium husks--do gastrointestinal adverse effects limit compliance? Results of a specific observational study.
Introduction Despite the known cholesterol reducing effect of psyllium seed husks (PSH) that has been shown in a number of studies (Garvin et al., 1965; Levin et al., 1990; Chan and Schroeder, 1995; Anderson et al., 2000), their use for therapy of mild or moderate hypercholesterolemia in...